Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on
Friday.
----------
AIM - WINNERS
----------
Petroneft Resources PLC, up 23% at 0.8 pence, 12-month range 0.55p-4.88p. Continues rebound after dropping 33% on Tuesday. Petroneft on Tuesday had said petroleum and fertilizer company Nord Imperial LLC had temporarily suspended oil acceptance and transfer from licence 61. Petroneft explains it now has no other export route from licence 61 and is now progressively shutting down its wells until the situation can be resolved. Production from Licence 67 is unaffected by the situation, it says.
----------
Shoe Zone PLC, up 17% at 169.9p, 12-month range 62p-205p. Resumes gains after the footwear retailer on Wednesday said trading has exceeded expectations since July on strong demand for summer and back-to-school products in August. As a result, adjusted pretax profit for the year ending October 2 is set to be at least GBP10.5 million, up from GBP9.5 million the year before.
----------
AIM - LOSERS
----------
Serinus Energy PLC, down 21% at 10.68p, 12-month range 9.3p-22.95p. Completes drilling operations at the Canar-1 exploration well in Romania, but notes disappointing results. Well logging and gas show readings show that the zones drilled did not contain sufficient gas resources to justify the completion of the well programme, Serinus says. As a result, the well will now be suspended for potential future use as a water disposal well. Serinus is a Jersey-based oil and gas company with operations focused in Romania and Tunisia.
----------
Alliance Pharma PLC, down 9.7% at 84.4p, 12-month range 84.1p-123p. Says it has appealed against the UK Completion & Markets Authority's decision to seek a competition disqualification order against its chief executive, Peter Butterfield. The CMA is seeking the disqualifications against a total of seven directors from four companies, including Alliance's Butterfield, over allegations of anti-competitive agreements in relation to the sale of prescription prochlorperazine. Alliance said it "fundamentally disagrees" with the CMA's actions and insists that Butterfield did not participate in, or profit from, any market sharing arrangement. He retains the full confidence and support of the Alliance board, it adds.
----------
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
